Pricing Log in Create free account
Saturday 17 October 2026 Export KPRX’s income statement to Excel — free account

Kiora Pharmaceuticals, Inc.

KPRX Healthcare Biotechnology

Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million. In the quarter to June 2026, EPS grew 37.0% and free cash flow grew 50.1%, each against the same quarter a year earlier.

2.40 0.01 −0.41%
Market cap
$10.7M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
n/a
Altman Z
−3.16
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 36.71%

Capital & Financial Ratios $m

Market Cap 10.66
Revenue 18.72
Net Income (10.99)
Free Cash Flow (8.61)
Net Debt (16.84)
Current Ratio 8.97 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.22) (negative: loss-making)
P/S ratio 0.79
P/B ratio 0.88
Past 5Y EPS Growth —
This Y EPS Growth 36.74% (at or above 15%: strong)
Next Y EPS Growth 49.10% (at or above 15%: strong)
Next Y revenue growth (90.64%) (below 0%: weak)
Next 5Y EPS Growth 28.62% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.1×, against a ten-year median of 0.9×; over the ten years it ranged from −4.3× in 2018 to 74.9× in 2022.
P/S against its own 10 years 24.17%
10-year low 10-year high
P/B against its own 10 years 43.24%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 2 27 17 17
Receivables 2 1 3 3
Inventory — — — —
Other — — 0 0
5 30 22 21
2023 2024 2025 Q'26
Payables 0 0 1 0
ST’ Debt — — — —
Other — 1 — —
2 6 4 2

Compound Annual Growth %

10y 5y 3y
Sales — 88.72% 113.23%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 10.23% 10.63% 12.23%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 16 0 — — 16
’20 — — — 0 0
’19 3 — — — 3
’18 1 0 0 — 2
’17 0 0 0 — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (2) — — —
’25 (3) (4) (1) (2) (10)
’24 14 (4) 1 (2) 9
’23 (3) (1) (3) (3) (10)
’22 (3) (2) (3) (2) (10)
’21 (3) (3) (2) (3) (11)
’20 (2) (1) (2) (2) (7)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (2) — — —
’25 (3) (4) (1) (2) (10)
’24 14 (4) 1 (2) 9
’23 (3) (1) (3) (3) (10)
’22 (3) (2) (3) (2) (10)
’21 (3) (3) (2) (3) (11)
’20 (2) (1) (2) (2) (7)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.58) (0.34) — — —
’25 (0.52) (0.54) 0.01 (1.60) (2.64)
’24 3.42 (0.53) (0.81) (1.04) 0.87
’23 (9.00) (7.11) (8.01) 0.20 (24.21)
’22 (97.21) (1.65) (54.27) (9.53) (166.97)
’21 (98.38) (126.01) (104.41) (280.83) (637.26)
’20 (154.81) (136.81) (158.42) (87.74) (637.26)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 5,994.00 4,860.00 1,485.00 810.00 1,152.00 288.00 20.88 4.16 3.00 1.77

Analyst estimates 2026–2028

Powerpack
High 27,540.00 21,060.00 7,236.00 4,640.40 3,668.40 2,826.00 511.20 76.64 8.98 4.18
People
People Employees 11 17 11 10 14 14 12 12 12 13
Revenue/emp, $m 0.06 0.02 0.15 0.27 0.00 0.00 0.00 0.00 1.34 0.00
Income, $m
Income, $m Revenue 1 0 2 3 0 — — — 16 —
Gross margin, % 100.00 100.00 100.00 100.00 100.00 0.00 0.00 — 100.00 —
EBT (13) (15) (11) (7) (7) (14) (14) (12) 6 (12)
EBT margin, % (1,993.64) (3,572.98) (649.04) (260.66) (56,609.09) 0.00 0.00 0.00 35.33 0.00
Net income (13) (13) (11) (7) (7) (14) (14) (13) 4 (11)
Depreciation 0 0 0 0 0 4 0 0 0 0
Per share, $
Per share, $ Revenue 418.31 156.73 250.38 305.23 0.95 0.00 0.00 0.00 4.14 0.00
Earnings (8,150.74) (5,019.99) (1,619.35) (802.88) (637.26) (637.26) (166.97) (24.21) 0.93 (2.60)
Cash flow (5,258.25) (2,487.88) (1,643.11) (926.57) (571.66) (398.34) (128.27) (17.76) 2.21 (2.39)
Capex (6.87) (14.23) (3.03) 0.00 (1.57) (2.38) 0.08 0.00 0.00 (0.03)
Free cash flow (5,265.12) (2,502.12) (1,646.14) (926.57) (573.23) (400.72) (128.19) (17.76) 2.21 (2.42)
Book value (205.87) (741.12) 1,353.98 752.56 760.13 544.00 140.31 11.36 6.65 3.87
Shares, m 0 0 0 0 0 0 0 1 4 4
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 — — — 1.51 —
P/S 0.00 27.69 9.60 7.32 6.98 — — — 0.68 —
P/B 0.00 0.00 1.85 4.79 2.33 — — — 0.50 —
EV/Sales 0.00 13.95 4.96 6.45 6.70 — — — (0.74) —
EV/FCF (1.29) (1.22) (0.79) (3.41) (2.95) — — — (1.62) —
Cash, $m
Cash, $m Operating cash flow (8) (6) (11) (8) (7) (11) (10) (10) 9 (10)
Capex 0 0 0 — 0 0 0 — 0 0
Free cash flow (8) (7) (11) (8) (7) (11) (10) (10) 9 (10)
Balance, $m
Balance, $m Working capital (3) (6) 5 3 0 7 4 3 24 18
Total debt 0 0 0 0 0 0 0 — — —
Net debt (4) (8) (8) (4) (1) (8) (6) (2) (27) (17)
Shareholders’ equity 0 (2) 9 7 10 15 11 6 26 16
Returns, %
Returns, % ROA (138.72) (109.98) (75.64) (58.19) (53.99) (77.72) (70.00) (80.55) 14.32 (35.68)
ROIC 0.00 0.00 (727.17) (156.13) (48.66) (132.31) (141.35) (215.23) 0.00 0.00
ROE (463.52) 1,171.64 (308.49) (91.23) (83.93) (113.30) (104.54) (148.94) 22.56 (51.74)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024

Charts ten years each

Kiora Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PTN Palatin Technologies, Inc. $11.6M — (loss-making) 0.2× −14.06% (below 0%: shrinking) n/m +34.21% (above 0%: growing) 100.00% (1,469.35%) Compare
CLRB Cellectar Biosciences, Inc. $11.2M — (loss-making) — −73.23% (below 0%: shrinking) n/m −17.49% (below 0%: shrinking) 0.00% 0.00% Compare
INTS Intensity Therapeutics Inc. $11.0M — (loss-making) — — n/m +4.72% (above 0%: growing) 0.00% 0.00% Compare
PHIO Phio Pharmaceuticals Corp. $10.8M — (loss-making) — (loss-making) −8.70% (below 0%: shrinking) n/m −58.67% (below 0%: shrinking) 0.00% 0.00% Compare
TPST Tempest Therapeutics, Inc. $10.7M — (loss-making) — −71.57% (below 0%: shrinking) n/m +67.04% (above 0%: growing) 0.00% 0.00% Compare
KPRX Kiora Pharmaceuticals, Inc. $10.7M — (loss-making) — (loss-making) −93.64% (below 0%: shrinking) n/m +50.06% (above 0%: growing) 100.00% 0.00%
GDTC CytoMed Therapeutics Limited $10.3M — (loss-making) — (loss-making) — n/m −27.39% (below 0%: shrinking) 0.00% — Compare
BLRX BioLineRx Ltd. $10.2M — (loss-making) — (loss-making) −3.29% (below 0%: shrinking) n/m −1,827.71% (below 0%: shrinking) 79.93% (1,215.31%) Compare
LTRN Lantern Pharma Inc. $10.0M — (loss-making) — — n/m +25.31% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $10.7M — — −14.06% — −6.38% 0.00% 0.00%

All 614 Biotechnology stocks →

Kiora Pharmaceuticals, Inc. (KPRX) key facts

  • Kiora Pharmaceuticals, Inc. (KPRX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million.
  • As of October 16, 2026, KPRX traded at $2.40, a market capitalization of $10.7 million.
  • Return on equity was −51.7% and debt-to-equity 0.00.
  • Its Altman Z-score is −3.16 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.

Kiora Pharmaceuticals, Inc. (KPRX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/KPRX · Data as of Jun 30, 2024 · For information only; not investment advice. · © 2026 stockrow.com